Guide

EU 2004/23/EC and the SoHO Regulation Transition: A Tissue Establishment Readiness Guide

Directive 2004/23/EC and the implementing Directives 2006/17/EC (donor eligibility and testing) and 2006/86/EC (traceability, serious adverse reactions and events, technical requirements) set the EU framework for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. The framework is currently transitioning to the Regulation on Substances of Human Origin (SoHO Regulation), agreed by EU institutions in 2024 and entering force on a staggered timeline through 2027–2028, which replaces the directives with a directly-applicable regulation, harmonises competent authority practice and tightens vigilance. This guide walks the current framework, the transition, the recurring inspection findings, and a practical path to a defensible tissue establishment file.

Start free trial Free trial, no credit card, onboard in days, not months.

The directive framework and competent authority authorisation

2004/23/EC requires every tissue establishment to be authorised, accredited, designated or licensed by the Member State competent authority for the specific activities carried out, with at least biennial inspection. The implementing Directive 2006/86/EC sets the technical requirements for accreditation. The recurring finding is an authorisation scope that has drifted out of step with the actual activities — a new tissue type, a new processing step or a new distribution route added without an authorisation variation.

Donor eligibility under 2006/17/EC and the SoHO update

2006/17/EC Annex II sets the donor selection criteria and Annex III the laboratory tests required. The SoHO Regulation will replace the directive with an updated risk-based donor eligibility framework, aligned with current epidemiology (HIV individual risk, HEV, emerging arboviruses). Establishments should be tracking the SoHO transition timeline at Member State level and preparing the rule-set update rather than waiting for the deadline.

Traceability, single European code and the Article 8 obligation

2006/86/EC Article 9 and the EU Tissue Establishment Compendium require traceability from donor to recipient and vice versa, with the Single European Code (SEC) applied to all tissues and cells distributed for human application since 2017. The SEC links the donation identification sequence (donating establishment, donation number) with the product identification sequence (product code, split number, expiry). Implementations that handle the data correctly but break the human-readable element or the linkage to the local record are the most common finding.

SARE reporting, vigilance and the SoHO vigilance update

2006/86/EC Article 5 and Article 6 require notification of Serious Adverse Reactions and Serious Adverse Events to the competent authority, with annual aggregated reports. The SoHO Regulation strengthens the vigilance system with a Union-level rapid alert mechanism and clearer obligations on cross-border notification. Tissue establishments that have run their SARE programme as a national obligation will need to broaden to Union-level alerting from the SoHO commencement date.

A 60-day readiness path

Days 1–10: competent authority authorisation reconciliation against actual activities. Days 11–25: donor eligibility rule refresh and SoHO transition mapping. Days 26–40: SEC implementation audit with attention to linkage integrity. Days 41–50: SARE/SAE workflow audit and Union-level rapid alert preparation. Days 51–60: internal audit, biennial inspection rehearsal and SoHO transition project plan refresh.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

EU tissue establishment QMS

2004/23 + 2006/17 + 2006/86 + SoHO ready.

Single European Code

Generated with linkage integrity.

SARE vigilance

National today, Union rapid alert ready.

Industries this hits hardest

Blood & tissue

Frequently asked

When does the SoHO Regulation enter into force?

The SoHO Regulation entered into force in 2024 with a staggered application timeline running through 2027–2028 for different provisions. Member State competent authorities are issuing transition guidance; the actual commencement of specific provisions varies.

Does 2004/23/EC apply to ATMPs?

2004/23/EC applies to the donation, procurement and testing of tissues and cells used as starting material for ATMPs; the manufacture of the ATMP itself is regulated under EU GMP (EudraLex Volume 4) and the Advanced Therapies Regulation 1394/2007. The boundary between the two frameworks must be explicitly handled.

Is the SEC required for autologous use?

The SEC requirement applies to tissues and cells distributed for human application, with specific provisions for autologous use. Member State competent authority guidance should be consulted for the local interpretation.

How does Brexit affect EU 2004/23/EC compliance for UK-EU tissue trade?

The UK now operates under the Human Tissue Act 2004 and HTA Quality and Safety regulations rather than the EU directive. Cross-border tissue trade requires both UK HTA licensing and EU competent authority authorisation, with traceability harmonised through technical agreement.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial Read the compliance brief →